Inactive Ingredient Search for Approved Drug Products
You are Searching: Change and Deletion by Inactive Ingredient Name Beginning with C
| Quarter | Inactive Ingredient | Route of Administration | Dosage Form | Maximum Potency per unit dose | Maximum Daily Exposure | Status | |
|---|---|---|---|---|---|---|---|
| Q1 2024 | CELLULOSE MICROCRYSTALLINE/CARBOXYMETHYLCELLULOSE SODIUM | NASAL | SPRAY, METERED | 60mg | Correction | ||
| Q2 2024 | CELLULOSE MICROCRYSTALLINE/CARBOXYMETHYLCELLULOSE SODIUM | NASAL | SPRAY, METERED | 8mg | Correction | ||
| Q1 2024 | CITRIC ACID MONOHYDRATE | ORAL | SUSPENSION | 330mg | Correction | ||
| Q2 2024 | CITRIC ACID MONOHYDRATE | ORAL | SUSPENSION | 269mg | Correction | ||
| Q2 2024 | CARRAGEENAN | TRANSDERMAL | FILM, EXTENDED RELEASE | 33.00 mg | Deletion | ||
| Q2 2024 | CETEARYL ETHYLHEXANOATE | TOPICAL | CREAM | 3.00 %w/w | Deletion | ||
| Q2 2024 | CITRIC ACID MONOHYDRATE | INTRAVENOUS | POWDER, FOR SOLUTION | 0.09 %w/v | Deletion | ||
| Q1 2024 | CARBOXYMETHYLCELLULOSE SODIUM | TOPICAL | SOLUTION | 0.50 %w/w | MDE Replacement | ||
| Q2 2024 | CARBOXYMETHYLCELLULOSE SODIUM | TOPICAL | SOLUTION | 3000mg | MDE Replacement | ||
| Q1 2024 | CITRIC ACID MONOHYDRATE | SUBCUTANEOUS | INJECTION | 1.26 %w/v | MDE Replacement | ||
| Q2 2024 | CITRIC ACID MONOHYDRATE | SUBCUTANEOUS | INJECTION | 28mg | MDE Replacement |
FDA/Center for Drug Evaluation and Research
Office of Pharmaceutical Quality
Office of Policy for Pharmaceutical Quality
Mailbox for IID corrections: IIDUpdate@fda.hhs.gov
Update Frequency: Quarterly
Data Through: March 15, 2024
Database Last Updated: April 29, 2024